Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.210
-0.060 (-2.64%)
Feb 21, 2025, 4:00 PM EST - Market closed
Nuvation Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 7.67, with a low estimate of 5.00 and a high estimate of 11. The average target predicts an increase of 247.06% from the current stock price of 2.21.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 23, 2025.
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $11 | Strong Buy | Maintains | $10 → $11 | +397.74% | Jan 23, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $6 → $10 | Buy | Reiterates | $6 → $10 | +352.49% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +216.74% | Jan 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $5 → $6 | Buy | Maintains | $5 → $6 | +171.49% | Nov 7, 2024 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +126.24% | Oct 22, 2024 |
Financial Forecast
Revenue This Year
2.21M
Revenue Next Year
10.49M
from 2.21M
Increased by 374.06%
EPS This Year
-2.20
from -0.35
EPS Next Year
-0.63
from -2.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.3M | 12.8M | 128.4M | |||
| Avg | 2.2M | 10.5M | 90.7M | |||
| Low | 2.1M | 9.0M | 54.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 479.0% | 1,123.5% | |||
| Avg | - | 374.1% | 764.1% | |||
| Low | - | 308.0% | 418.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -2.19 | -0.58 | -0.46 | |
| Avg | -2.20 | -0.63 | -0.52 | |
| Low | -2.22 | -0.67 | -0.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.